中医药联合EGFR-TKIS治疗非小细胞肺癌研究进展

Research Progress of TCM Combined with EGFR-TKIS in the Treatment of Non-Small-Cell Lung Cancer

表皮生长因子受体酪氨酸酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors,EGFR-TKIS)可抑制肿瘤生长,广泛应用于肿瘤的治疗,但存在不良反应和耐药等问题。中医药治疗非小细胞肺癌(non-small-cell lung cancer,NSCLC)以其精准化、个体化、多靶点等优势,贯穿整个肿瘤治疗过程,同时中药在改善靶向治疗引起的不良反应、增强药物疗效、延缓耐药、提升患者生活质量等方面疗效显著。但同时,中医药联合EGFR-TKIS治疗NSCLC的作用机制尚不明了,大多临床研究不符合高级别循证医学的要求。由于中医辨证论治因人而异的特殊性,在非小细胞肺癌治疗的中医分型、中药的不良反应等方面尚无统一标准。今后,应开展中医药联合EGFR-TKIS治疗NSCLC的多中心大样本临床研究,同时进一步深入探讨其作用机制和不良反应。

Epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIS)can inhibit tumor growth and is widely used in the treatment of tumor,but there are some problems such as side effects and drug resistance.TCM in the treatment of non-small-cell lung cancer(NSCLC)with its advantages of precision,individualization and multi-target runs through the whole process of tumor treatment.At the same time,Chinese medicinals have significant effect in improving the side effects caused by targeted treatment,increasing drug efficacy,delaying drug resistance and improving the quality of life of patients.But at the same time,the mechanism of TCM combined with EGFR-TKIS in the treatment of NSCLC is still unclear,and most clinical studies do not meet the requirements of high-level evidence-based medicine.Due to the particularity of TCM syndrome differentiation and treatment,there is no unified standard of TCM classification and toxic and side effects in the treatment of NSCLC.In the future,it is necessary to carry out the multi-center and large sample clinical study of TCM combined with EGFR-TKIS in the treatment of NSCLC,and further explore its mechanism of action and adverse reactions.